STAT+: With new data, J&J’s CAR-T drug benefits myeloma patients with less advanced disease
When doctors prescribe a personalized cell therapy today, the patient they’re trying to help has blood cancer so advanced other medicines no longer work. In the future, these so-called CAR-T treatments might be used earlier, for greater benefit, when cancer patients aren’t so desperately sick.
Toward that goal, a CAR-T therapy called cilta-cel from Johnson & Johnson was more effective and better tolerated when used to treat patients with less advanced multiple myeloma, according to preliminary study results released Wednesday.
